Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

February 28, 2025

Conditions

Prostate Cancers

Interventions

DRUG

One single intravenous injection of [177Lu]Lu-BQ7876

One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.

Trial Locations (1)

TomskNRMC, Tomsk

All Listed Sponsors

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT06641219 - Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen | Biotech Hunter | Biotech Hunter